Compare ABR & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABR | ANAB |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2004 | 2017 |
| Metric | ABR | ANAB |
|---|---|---|
| Price | $7.76 | $47.57 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 12 |
| Target Price | $10.20 | ★ $60.18 |
| AVG Volume (30 Days) | ★ 3.5M | 482.0K |
| Earning Date | 02-20-2026 | 02-26-2026 |
| Dividend Yield | ★ 15.50% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $552,909,000.00 | $169,467,000.00 |
| Revenue This Year | N/A | $135.51 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.72 | ★ N/A |
| Revenue Growth | N/A | ★ 196.42 |
| 52 Week Low | $7.58 | $12.21 |
| 52 Week High | $14.33 | $52.47 |
| Indicator | ABR | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 39.98 | 54.75 |
| Support Level | $7.69 | $44.25 |
| Resistance Level | $8.24 | $48.53 |
| Average True Range (ATR) | 0.28 | 2.96 |
| MACD | 0.05 | -0.20 |
| Stochastic Oscillator | 19.70 | 66.35 |
Arbor Realty Trust Inc is a specialized real estate finance company. It invests in a diversified portfolio of structured finance assets in the multifamily and commercial real estate markets, consisting of bridge and mezzanine loans, including junior participating interests in first mortgages, preferred, and direct equity. In addition, it may also directly acquire real property and invest in real estate-related notes and certain mortgage-related securities. The company has two business segments, Structured Business and Agency Business. It generates a majority of its revenue from the Structured Business Segment. The company is externally managed and advised by Arbor Commercial Mortgage, LLC.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).